Fig. 4
From: Inhibition of effector B cells by ibrutinib in systemic sclerosis
Subset analysis of IL-6 production via intracellular cytokine staining. PBMCs of patients with SSc (n = 10) were incubated with CpG (0.1 μM) for 24 h under ibrutinib treatment; DMSO (0.1%) was used as control. a Percentage of naïve and memory B cells of all B cells in unstimulated controls. b Ibrutinib treatment reduces the amount of IL-6+ naïve (CD27−) B cells significantly at low dosages, while no significant change was observed in the subset of memory B cells (CD27+). Bars represent mean. Error bars indicate SEM. *p < 0.05, **p < 0.01. c Representative dot plots of naïve (CD27−) B cells. d Representative dot plots of memory (CD27+) B cells